FDA approves LPI's Perindopril Erbumine tablets

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the U.S. Food and Drug Administration (U.S. FDA) for its Perindopril Erbumine tablets, 2mg, 4mg and 8mg.  Commercial shipments of the product will commence shortly.

Lupin's Perindopril Erbumine tablets are AB-rated to ACEON®* tablets indicated for the treatment of patients with essential hypertension and can be used with conventional treatment for management of coronary artery disease.  ACEON had annual sales of approximately $24 million for the twelve months ended September 2009, based on IMS Health sales data.